Global Anticoagulation Therapy Market, By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran, Edoxaban, Betrixaban, Rivaroxaban, Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights of Anticoagulation Therapy
Anticoagulation therapy market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.80% in the above mentioned forecast period.
Anticoagulation therapy is a type of medicine used in preclusion of blood clots formation and to endorse blood vessels open. Anticoagulants are generally called as blood thinners but actually they do not act so and only helps to avoid or to lessen blood clot formation.
The increasing prevalence of arrhythmia, blood vessel thromboembolism and stroke is amongst the important factors intensifying the growth and demand of anticoagulation therapy market. In addition, the rising acceptance of NOAC’s is also contributing to rising in the global market over the forecast period of 2021 to 2028. Also the increasing outpatient anticoagulation therapy and growing heparin trade are also enhancing the growth of the market. Likewise, the increasing awareness regarding anti-coagulants therapy among physicians, prevalence of cardiovascular diseases such as coronary artery disease, rise in R&D for the innovation of novel oral anticoagulants, surge in the use of anticoagulants as alternative to antiplatelet drugs, wide range of applications of anticoagulants, and increase in blood transfusions are also lifting the market growth in the above mentioned forecast period. The rising investments in research and growing number of pipeline products under clinical trials will further accelerate the expansion of the anticoagulation therapy market and are also are offering significant growth opportunities for the market in the forecast period of 2021 to 2028.
However, the lack of antidote for NOACs and high cost of developing drugs will curb the growth of the anticoagulation therapy market, whereas the high risk of malfunctions like increased bleeding have the potential to challenge the growth of the anticoagulation therapy market.
This anticoagulation therapy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on anticoagulation therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Anticoagulation Therapy Market Scope and Market Size
Anticoagulation therapy market is segmented on the basis of treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of treatment, the anticoagulation therapy market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others.
- On the basis of therapeutic class, the anticoagulation therapy market is segmented into novel oral anticoagulants (noac), heparin, vitamin k antagonists and others.
- Based on drug type, the anticoagulation therapy market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others.
- On the basis of route of administration, the anticoagulation therapy market is segmented into oral and Injectable.
- Based on therapeutic area, the anticoagulation therapy market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others.
- On the basis of procedure, the anticoagulation therapy market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement.
- On the basis of type, the anticoagulation therapy market is segmented into generics and branded.
- The end user segment of anticoagulation therapy market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others.
- Based on distribution channel, the anticoagulation therapy market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Anticoagulation Therapy Market Country Level Analysis
Anticoagulation therapy market is analyzed and market size insights and trends are provided by country, treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.
The countries covered in the anticoagulation therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.
North America region leads the anticoagulation therapy market owing to the increasing number of the hospital associated clinics and high healthcare expenditure within the region. Asia-Pacific is expected to expand at a significant growth rate over the forecast period of 2021 to 2028 because of the enduring administration and growing chronic sales of anticoagulation drugs for long lasting medical aid therapy in this particular region.
The country section of the anticoagulation therapy market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Anticoagulation therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for anticoagulation therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the anticoagulation therapy market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Anticoagulation Therapy Market Share Analysis
Anticoagulation therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to anticoagulation therapy market.
The major players covered in the anticoagulation therapy market report are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical(Group)Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo International plc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., and Taro Pharmaceutical Industries Ltd., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-